journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Heart Failure

journal
https://www.readbyqxmd.com/read/30311713/screening-diagnosis-and-treatment-of-iron-deficiency-in-chronic-heart-failure-putting-the-2016-european-society-of-cardiology-heart-failure-guidelines-into-clinical-practice
#1
REVIEW
Theresa McDonagh, Thibaud Damy, Wolfram Doehner, Carolyn S P Lam, Andrew Sindone, Peter van der Meer, Alain Cohen-Solal, Ingrid Kindermann, Nicolas Manito, Otmar Pfister, Hanna Pohjantähti-Maaroos, Jackie Taylor, Josep Comin-Colet
Iron deficiency is common in patients with chronic heart failure (CHF) and is associated with reduced exercise performance, impaired health-related quality of life and an increased risk of mortality, irrespective of whether or not anaemia is present. Iron deficiency is a serious but treatable condition. Several randomized controlled clinical trials have demonstrated the ability of intravenous (IV) iron, primarily IV ferric carboxymaltose (FCM), to correct iron deficiency in patients with heart failure with reduced ejection fraction (HFrEF), resulting in improvements in exercise performance, CHF symptoms and health-related quality of life...
October 12, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30303611/phrenic-nerve-stimulation-to-treat-patients-with-central-sleep-apnoea-and-heart-failure
#2
Maria Rosa Costanzo, Piotr Ponikowski, Andrew Coats, Shahrokh Javaheri, Ralph Augostini, Lee R Goldberg, Richard Holcomb, Andrew Kao, Rami N Khayat, Olaf Oldenburg, Christoph Stellbrink, Scott McKane, William T Abraham
AIMS: The presence of central sleep apnoea (CSA) is associated with poor prognosis in patients with heart failure (HF). The aim of this analysis was to evaluate if using phrenic nerve stimulation to treat CSA in patients with CSA and HF was associated with changes in HF-specific metrics. METHODS AND RESULTS: All patients randomized in the remedē System Pivotal Trial and identified at baseline with HF were included (n = 96). Effectiveness data from treatment and former control groups were pooled based on months since therapy activation...
October 10, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30298968/exercise-training-in-heart-failure-a-long-way-to-go-yet
#3
EDITORIAL
Hitesh C Patel, David M Kaye
No abstract text is available yet for this article.
October 9, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30295999/developing-evidence-based-and-accountable-health-policy-in-heart-failure
#4
Cian P McCarthy, Muthiah Vaduganathan, Ambarish Pandey
No abstract text is available yet for this article.
October 8, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30295978/talking-to-patients-with-heart-failure-about-end-of-life
#5
LETTER
Ross T Campbell, Mark C Petrie, John J V McMurray
No abstract text is available yet for this article.
October 8, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30295977/what-is-the-added-value-of-the-waist-to-hip-ratio-on-top-of-the-biostat-risk-prediction-model-in-patients-with-heart-failure-reply
#6
LETTER
Koen W Streng, Chim C Lang, Adriaan A Voors
No abstract text is available yet for this article.
October 8, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30280460/molecular-and-pathophysiological-links-between-heart-failure-with-preserved-ejection-fraction-and-type-2-diabetes-mellitus
#7
Zoltán Papp, Tamás Radovits, Walter J Paulus, Nazha Hamdani, Petar M Seferović
No abstract text is available yet for this article.
October 2, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30280454/frailty-in-topcat-a-deep-dive-into-the-deficit-index-approach-for-defining-frailty
#8
EDITORIAL
Kelsey Flint
No abstract text is available yet for this article.
October 2, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30280452/patient-reported-and-morbidity-mortality-endpoints-can-one-have-the-best-of-both-worlds
#9
EDITORIAL
João Pedro Ferreira, Faiez Zannad
No abstract text is available yet for this article.
October 2, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30255969/impact-of-exercise-based-cardiac-rehabilitation-in-patients-with-heart-failure-extramatch-ii-on-mortality-and-hospitalisation-an-individual-patient-data-meta-analysis-of-randomised-trials
#10
Rod S Taylor, Sarah Walker, Neil A Smart, Massimo F Piepoli, Fiona C Warren, Oriana Ciani, Christopher O'Connor, David Whellan, Steven J Keteyian, Andrew Coats, Constantinos H Davos, Hasnain M Dalal, Kathleen Dracup, Lorraine Evangelista, Kate Jolly, Jonathan Myers, Robert S McKelvie, Birgitta B Nilsson, Claudio Passino, Miles D Witham, Gloria Y Yeh, Ann-Dorthe O Zwisler
AIMS: To undertake an individual patient data (IPD) meta-analysis to assess the impact of exercise-based cardiac rehabilitation (ExCR) in patients with heart failure (HF) on mortality and hospitalisation, and differential effects of ExCR according to patient characteristics: age, sex, ethnicity, New York Heart Association functional class, ischaemic aetiology, ejection fraction, and exercise capacity. METHODS AND RESULTS: Randomised trials of exercise training for at least 3 weeks compared with no exercise control with 6-month follow-up or longer, providing IPD time to event on mortality or hospitalisation (all-cause or HF-specific)...
September 26, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30238574/rationale-and-design-of-the-advor-acetazolamide-in-decompensated-heart-failure-with-volume-overload-trial
#11
Wilfried Mullens, Frederik H Verbrugge, Petra Nijst, Pieter Martens, Katrien Tartaglia, Evi Theunissen, Liesbeth Bruckers, Walter Droogne, Pierre Troisfontaines, Kevin Damman, Johan Lassus, Alexandre Mebazaa, Gerasimos Filippatos, Frank Ruschitzka, Matthias Dupont
AIMS: Decisive evidence on the optimal diuretic agent, dosing schedule, and administration route is lacking in acute heart failure (AHF) with congestion. The Acetazolamide in Decompensated heart failure with Volume OveRload (ADVOR) trial is designed to test the hypothesis that the carbonic anhydrase inhibitor acetazolamide, a potent inhibitor of proximal tubular sodium reabsorption, improves decongestion when combined with loop diuretic therapy in AHF, potentially leading to better clinical outcomes...
September 21, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30230666/telemedical-interventional-management-in-heart-failure-ii-tim-hf2-a-randomised-controlled-trial-investigating-the-impact-of-telemedicine-on-unplanned-cardiovascular-hospitalisations-and-mortality-in-heart-failure-patients-study-design-and-description-of-the
#12
Friedrich Koehler, Kerstin Koehler, Oliver Deckwart, Sandra Prescher, Karl Wegscheider, Sebastian Winkler, Eik Vettorazzi, Andreas Polze, Karl Stangl, Oliver Hartmann, Almuth Marx, Petra Neuhaus, Michael Scherf, Bridget-Anne Kirwan, Stefan D Anker
BACKGROUND: Heart failure (HF) is a complex, chronic condition that is associated with debilitating symptoms, all of which necessitate close follow-up by health care providers. Lack of disease monitoring may result in increased mortality and more frequent hospital readmissions for decompensated HF. Remote patient management (RPM) in this patient population may help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a manifestation of HF decompensation...
September 19, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30225959/advanced-heart-failure-trans-atlantic-perspectives-on-the-heart-failure-association-of-the-european-society-of-cardiology-position-statement
#13
EDITORIAL
Barry Greenberg, James Fang, Mandeep Mehra, Lynne Warner Stevenson
No abstract text is available yet for this article.
September 18, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30225950/muscling-up-to-improve-heart-failure-prognosis
#14
EDITORIAL
Hector O Ventura, Salvatore Carbone, Carl J Lavie
No abstract text is available yet for this article.
September 18, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30225878/the-frailty-syndrome-and-outcomes-in-the-topcat-trial
#15
Natalie A Sanders, Mark A Supiano, Eldrin F Lewis, Jiankang Liu, Brian Claggett, Marc A Pfeffer, Akshay S Desai, Nancy K Sweitzer, Scott D Solomon, James C Fang
AIMS: The impact of frailty on outcomes in randomized heart failure with preserved ejection fraction (HFpEF) trials has not been previously reported. This analysis sought to characterize frailty in a large contemporary HFpEF clinical trial cohort and to evaluate its impact on patient relevant outcomes. METHODS AND RESULTS: Using data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, a frailty index (FI) was constructed at baseline using 39 clinical, laboratory, and self-reported variables...
September 18, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30225956/is-mild-asymptomatic-left-ventricular-systolic-dysfunction-always-predictive-of-adverse-events-in-high-risk-populations-insights-from-the-david-berg-study
#16
Mauro Gori, Margaret M Redfield, Alice Calabrese, Paolo Canova, Giovanni Cioffi, Renata De Maria, Aurelia Grosu, Alessandra Fontana, Attilio Iacovoni, Paola Ferrari, Gianfranco Parati, Antonello Gavazzi, Michele Senni
BACKGROUND: Mild asymptomatic left ventricular systolic dysfunction (ALVSD) may be associated with incident heart failure (HF). However, this gray zone group needs incremental risk refinement. We hypothesized that diastolic dysfunction (DD) may refine HF and death risk prediction in mild ALVSD. METHODS AND RESULTS: Among 4047 subjects aged ≥55/≤80 years followed by 10 general practitioners in northern Italy, the DAVID-Berg study prospectively enrolled 623 asymptomatic outpatients at increased risk for HF...
September 17, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30225884/the-epicardial-adipose-inflammatory-triad-coronary-atherosclerosis-atrial-fibrillation-and-heart-failure-with-a-preserved-ejection-fraction
#17
EDITORIAL
Milton Packer
No abstract text is available yet for this article.
September 17, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30225882/rationale-and-design-of-the-phase-2b-clinical-trials-to-study-the-effects-of-the-partial-adenosine-a1-receptor-agonist-neladenoson-bialanate-in-patients-with-chronic-heart-failure-with-reduced-pantheon-and-preserved-panache-ejection-fraction
#18
Adriaan A Voors, Sanjiv J Shah, Jeroen J Bax, Javed Butler, Mihai Gheorghiade, Adrian F Hernandez, Dalane W Kitzman, John J V McMurray, Antonieta Bomfim Wirtz, Vivian Lanius, Michael van der Laan, Scott D Solomon
Despite major advances in the treatment of chronic heart failure (HF) with reduced ejection fraction (HFrEF), morbidity and mortality associated with the condition remain high, suggesting the need for additional treatment options, particularly haemodynamically neutral treatments that do not alter blood pressure, heart rate, or renal function. HF with preserved ejection fraction (HFpEF) is also associated with high morbidity and mortality and adequate treatment options are limited; thus there is a critical unmet need for the development of novel therapies for HFpEF...
September 17, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30204280/growth-differentiation-factor-15-is-not-modified-by-sacubitril-valsartan-and-is-an-independent-marker-of-risk-in-patients-with-heart-failure-and-reduced-ejection-fraction-the-paradigm-hf-trial
#19
Nadia Bouabdallaoui, Brian Claggett, Michael R Zile, John J V McMurray, Eileen O'Meara, Milton Packer, Margarett F Prescott, Karl Swedberg, Scott D Solomon, Jean L Rouleau
AIMS: Growth differentiation factor-15 (GDF-15) is associated with adverse prognosis in cardiovascular (CV) and non-CV diseases. We evaluated the association of GDF-15 with CV and non-CV outcomes in the PARADIGM-HF trial. METHODS AND RESULTS: In 1935 patients with heart failure and reduced ejection fraction (HFrEF) in PARADIGM-HF, median GDF-15 values were elevated and similar in sacubitril/valsartan and enalapril patients (1626 ng/L and 1690 ng/L, respectively)...
September 11, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/30191648/activation-of-protein-phosphatase-1-by-a-selective-phosphatase-disrupting-peptide-reduces-sarcoplasmic-reticulum-ca-2-leak-in-human-heart-failure
#20
Thomas H Fischer, Jörg Eiringhaus, Nataliya Dybkova, Alireza Saadatmand, Steffen Pabel, Silvio Weber, Yansong Wang, Maja Köhn, Theodor Tirilomis, Senka Ljubojevic, André Renner, Jan Gummert, Lars S Maier, Gerd Hasenfuß, Ali El-Armouche, Samuel Sossalla
BACKGROUND: Disruption of Ca2+ homeostasis is a key pathomechanism in heart failure. CaMKII-dependent hyperphosphorylation of ryanodine receptors in the sarcoplasmic reticulum (SR) increases the arrhythmogenic SR Ca2+ leak and depletes SR Ca2+ stores. The contribution of conversely acting serine/threonine phosphatases [protein phosphatase 1 (PP1) and 2A (PP2A)] is largely unknown. METHODS AND RESULTS: Human myocardium from three groups of patients was investigated: (i) healthy controls (non-failing, NF, n = 8), (ii) compensated hypertrophy (Hy, n = 16), and (iii) end-stage heart failure (HF, n = 52)...
September 7, 2018: European Journal of Heart Failure
journal
journal
34664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"